| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 17MM | +13% |
| Gross Profit | 11.6MM | +12% |
| Cost Of Revenue | 5.3MM | +16% |
| Operating Income | -12.3MM | +21% |
| Operating Expenses | 23.9MM | +16% |
| Net Income | -12.9MM | +18% |
| R&D | 2.7MM | +13% |
| G&A | 4.1MM | +9% |
| Marketing | 17.2MM | +19% |
| Interest Expense | 1.3MM | +1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.)MALVERN, Pa., April 15, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the U.S. launch of OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, specifically designed for use in laparoscopic and robotic-assisted inguinal hernia repair. OviTex IHR is
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgeryMALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is
Investors in TELA Bio, Inc. ( NASDAQ:TELA ) had a good week, as its shares rose 7.5% to close at US$5.73 following the...
TELA Bio ( NASDAQ:TELA ) Full Year 2023 Results Key Financial Results Revenue: US$58.5m (up 41% from FY 2022). Net...
TELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcript March 21, 2024 TELA Bio, Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.44. TELA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon ladies and […]
Q4 2023 TELA Bio Inc Earnings Call
TELA Bio Inc (TELA) Announces Earnings with Significant Sales Increase and Strategic Product Launches
TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter and $58.5 million for the f